Could ICON Public Limited Company (ICLR) Skyrocket Even More? The Stock Just Made 52-Week High

June 14, 2018 - By Clifton Ray

ICON Public Limited Company (NASDAQ:ICLR) Logo

The stock of ICON Public Limited Company (NASDAQ:ICLR) hit a new 52-week high and has $144.34 target or 6.00 % above today’s $136.17 share price. The 5 months bullish chart indicates low risk for the $7.33B company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $144.34 price target is reached, the company will be worth $439.50 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.75% or $1.01 during the last trading session, reaching $136.17. About 100,345 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 38.08% since June 14, 2017 and is uptrending. It has outperformed by 25.51% the S&P500.

Analysts await ICON Public Limited Company (NASDAQ:ICLR) to report earnings on July, 26. They expect $1.48 earnings per share, up 12.98 % or $0.17 from last year’s $1.31 per share. ICLR’s profit will be $79.61 million for 23.00 P/E if the $1.48 EPS becomes a reality. After $1.42 actual earnings per share reported by ICON Public Limited Company for the previous quarter, Wall Street now forecasts 4.23 % EPS growth.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

Among 7 analysts covering Icon plc (NASDAQ:ICLR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Icon plc had 10 analyst reports since January 9, 2018 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, January 9 with “Buy”. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “In-Line” rating by Evercore on Tuesday, April 3. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by Credit Suisse on Thursday, February 15. As per Wednesday, January 10, the company rating was maintained by KeyBanc Capital Markets. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Hold” rating by Mizuho on Wednesday, January 24. Jefferies maintained ICON Public Limited Company (NASDAQ:ICLR) on Thursday, February 15 with “Buy” rating. The stock has “Buy” rating by Robert W. Baird on Thursday, February 15. SunTrust maintained it with “Buy” rating and $133.0 target in Monday, January 22 report. Mizuho maintained ICON Public Limited Company (NASDAQ:ICLR) on Thursday, February 15 with “Hold” rating.

More recent ICON Public Limited Company (NASDAQ:ICLR) news were published by: Businesswire.com which released: “ICON Enhances Endpoint Adjudication Services Using AG Mednet Advanced Technology” on June 11, 2018. Also 247Wallst.com published the news titled: “4 Pharmaceutical Services Stocks To Buy With Big Upside Potential” on June 13, 2018. Nasdaq.com‘s news article titled: “Investor Expectations to Drive Momentum within Momo, Barrick Gold, Grupo Financiero Santander Mexico SAB de CV …” with publication date: June 04, 2018 was also an interesting one.

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $7.33 billion. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 26.54 P/E ratio. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: